001     130415
005     20240228143431.0
024 7 _ |a 10.18632/oncotarget.10665
|2 doi
024 7 _ |a pmid:27437873
|2 pmid
024 7 _ |a pmc:PMC5312293
|2 pmc
024 7 _ |a altmetric:17885788
|2 altmetric
037 _ _ |a DKFZ-2017-05494
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Ríos-Tamayo, Rafael
|b 0
245 _ _ |a A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.
260 _ _ |a [S.l.]
|c 2016
|b Impact Journals LLC
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1522227456_30778
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Diabetogenic single nucleotide polymorphisms (SNPs) have recently been associated with multiple myeloma (MM) risk but their impact on overall survival (OS) of MM patients has not been analysed yet. In order to investigate the impact of 58 GWAS-identified variants for type 2 diabetes (T2D) on OS of patients with MM, we analysed genotyping data of 936 MM patients collected by the International Multiple Myeloma rESEarch (IMMENSE) consortium and an independent set of 700 MM patients recruited by the University Clinic of Heidelberg. A meta-analysis of the cox regression results of the two sets showed that rs7501939 located in the HNF1B gene negatively impacted OS (HRRec= 1.44, 95% CI = 1.18-1.76, P = 0.0001). The meta-analysis also showed a noteworthy gender-specific association of the SLC30A8rs13266634 SNP with OS. The presence of each additional copy of the minor allele at rs13266634 was associated with poor OS in men whereas no association was seen in women (HRMen-Add = 1.32, 95% CI 1.13-1.54, P = 0.0003). In conclusion, these data suggest that the HNF1Brs7501939 SNP confers poor OS in patients with MM and that a SNP in SLC30A8 affect OS in men.
536 _ _ |a 313 - Cancer risk factors and prevention (POF3-313)
|0 G:(DE-HGF)POF3-313
|c POF3-313
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Lupiañez, Carmen Belén
|b 1
700 1 _ |a Campa, Daniele
|b 2
700 1 _ |a Hielscher, Thomas
|0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
|b 3
|u dkfz
700 1 _ |a Weinhold, Niels
|b 4
700 1 _ |a Martínez-López, Joaquin
|b 5
700 1 _ |a Jerez, Andrés
|b 6
700 1 _ |a Landi, Stefano
|b 7
700 1 _ |a Jamroziak, Krzysztof
|b 8
700 1 _ |a Dumontet, Charles
|b 9
700 1 _ |a Wątek, Marzena
|b 10
700 1 _ |a Lesueur, Fabienne
|b 11
700 1 _ |a Reis, Rui Manuel
|b 12
700 1 _ |a Marques, Herlander
|b 13
700 1 _ |a Jurczyszyn, Artur
|b 14
700 1 _ |a Vogel, Ulla
|b 15
700 1 _ |a Buda, Gabriele
|b 16
700 1 _ |a García-Sanz, Ramón
|b 17
700 1 _ |a Orciuolo, Enrico
|b 18
700 1 _ |a Petrini, Mario
|b 19
700 1 _ |a Vangsted, Annette J
|b 20
700 1 _ |a Gemignani, Federica
|b 21
700 1 _ |a Försti, Asta
|0 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
|b 22
|u dkfz
700 1 _ |a Goldschmidt, Hartmut
|b 23
700 1 _ |a Hemminki, Kari
|0 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
|b 24
|u dkfz
700 1 _ |a Canzian, Federico
|0 P:(DE-He78)5323704270b6393dcea70186ffd86bca
|b 25
|u dkfz
700 1 _ |a Jurado, Manuel
|b 26
700 1 _ |a Sainz, Juan
|b 27
773 _ _ |a 10.18632/oncotarget.10665
|g Vol. 7, no. 37, p. 59029 - 59048
|0 PERI:(DE-600)2560162-3
|n 37
|p 59029 - 59048
|t OncoTarget
|v 7
|y 2016
|x 1949-2553
909 C O |o oai:inrepo02.dkfz.de:130415
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)5323704270b6393dcea70186ffd86bca
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|2 G:(DE-HGF)POF3-300
|v Cancer risk factors and prevention
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2016
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ONCOTARGET : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ONCOTARGET : 2015
920 1 _ |0 I:(DE-He78)C050-20160331
|k C050
|l Molekular-Genetische Epidemiologie
|x 0
920 1 _ |0 I:(DE-He78)C055-20160331
|k C055
|l Genomische Epidemiologie
|x 1
920 1 _ |0 I:(DE-He78)G180-20160331
|k G180
|l Molekulare Grundlagen Gastrointestinaler Tumoren
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C050-20160331
980 _ _ |a I:(DE-He78)C055-20160331
980 _ _ |a I:(DE-He78)G180-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21